ClearPoint Neuro (CLPT) Expected to Announce Earnings on Monday

ClearPoint Neuro (NASDAQ:CLPT) is expected to be announcing its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $12.7330 million for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 3, 2026 at 4:30 PM ET.

ClearPoint Neuro (NASDAQ:CLPT) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.04). The business had revenue of $12.13 million during the quarter, compared to analysts’ expectations of $11.97 million. ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Price Performance

Shares of CLPT opened at $14.94 on Friday. The business’s 50-day moving average is $15.38 and its two-hundred day moving average is $13.07. The company has a market capitalization of $448.05 million, a P/E ratio of -14.79 and a beta of 1.23. ClearPoint Neuro has a fifty-two week low of $8.27 and a fifty-two week high of $30.10. The company has a debt-to-equity ratio of 2.63, a quick ratio of 4.88 and a current ratio of 5.79.

Insider Activity

In other ClearPoint Neuro news, CEO Joseph Burnett sold 60,000 shares of ClearPoint Neuro stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $17.79, for a total value of $1,067,400.00. Following the completion of the transaction, the chief executive officer owned 116,842 shares of the company’s stock, valued at approximately $2,078,619.18. The trade was a 33.93% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Matthew B. Klein sold 16,000 shares of the stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $11.59, for a total transaction of $185,440.00. Following the sale, the director directly owned 46,935 shares in the company, valued at approximately $543,976.65. The trade was a 25.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 108,349 shares of company stock worth $1,796,118 over the last three months. Corporate insiders own 6.94% of the company’s stock.

Hedge Funds Weigh In On ClearPoint Neuro

A number of large investors have recently bought and sold shares of CLPT. NewEdge Advisors LLC acquired a new stake in ClearPoint Neuro in the fourth quarter valued at approximately $235,000. XTX Topco Ltd purchased a new stake in shares of ClearPoint Neuro in the fourth quarter valued at approximately $300,000. Millennium Management LLC raised its stake in shares of ClearPoint Neuro by 174.4% during the 4th quarter. Millennium Management LLC now owns 515,375 shares of the company’s stock worth $7,050,000 after buying an additional 327,574 shares during the period. Balyasny Asset Management L.P. acquired a new position in shares of ClearPoint Neuro during the 4th quarter worth approximately $2,972,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of ClearPoint Neuro by 4.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 26,791 shares of the company’s stock worth $367,000 after buying an additional 1,204 shares during the period. Institutional investors and hedge funds own 30.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Stifel Nicolaus set a $16.00 target price on ClearPoint Neuro in a research note on Tuesday, June 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a research report on Friday, July 17th. Finally, B. Riley Financial boosted their price target on ClearPoint Neuro from $20.00 to $30.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $23.00.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.